Jon-san Wrote:Sorry, just a quick question here? What are buy-sides and sell-sides? What stands do they hold? A little confused.
In the investing world, "buy side" refers to the folks that actually invest money. So for example a fund run by Fidelity or Aberdeen, or me, would be from the buy side. We buy securities on behalf of our clients. The buy-side will normally do its own research, using the sell-side research as a check or secondary reference.
"Sell side" refers to the brokers who write research reports hoping that the buy-side will reward them with brokerage business. Sometimes the reports are freely distributed, other times they are sent to clients only. Both the brokers who serve retail investors as well as those that serve institutional investors are regarded as the sell-side. So for example both Phillip Securities and Goldman Sachs would be from the sell-side.
If you think about it, the sell-side arrangement is ridiculous. They provide research with no guarantee of business, and since they are paid by trading commissions the incentive is to always write a good story in order to drive trading volume and retain corporate access to information. Most broking houses also do investment banking, so there is yet another incentive to write a nice story, so that they can land investment banking business (secondary debt/equity offerings) from the company.
There were some attempts in the past to set up independent research houses but most found that the buy-side didn't want to pay for research even if it was clearly independent. The few outfits that survive today are mostly niche providers e.g. credit or forensic specialists who serve hedge funds looking for stuff to short.
The no-research brokers who provide cheap trading commissions have been more successful. E-trade, Charles Schwab and Interactive Brokers are some examples of brokers who have become very successful with a low-fee model. Most big buy-side operations still go through full-service brokers, as their size allows them to negotiate down the commissions and still retain the perks i.e. "free" research and corporate access.